Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.

CK2 (casein kinase 2) is a serine/threonine protein kinase that is ubiquitous in eukaryotic cells and plays important roles in a variety of cellular functions, including cell growth, apoptosis, circadian rhythms, DNA damage repair, transcription, and translation. CK2 is involved in cancer pathogenesis and the occurrence of many diseases. Therefore, targeting CK2 is a promising therapeutic strategy. Although many CK2-specific small-molecule inhibitors have been developed, only CX-4945 has progressed to clinical trials. In recent years, novel CK2 inhibitors have gradually become a research hotspot, which is expected to overcome the limitations of traditional inhibitors. Herein, we summarize the structure, biological functions, and disease relevance of CK2 and emphatically analyze the structure-activity relationship (SAR) and binding modes of small-molecule CK2 inhibitors. We also discuss the latest progress of novel strategies, providing insights into new drugs targeting CK2 for clinical practice.

[1]  Dan Zhang,et al.  Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases. , 2023, European journal of medicinal chemistry.

[2]  B. Kren,et al.  Protein kinase CK2 – diverse roles in cancer cell biology and therapeutic promise , 2022, Molecular and Cellular Biochemistry.

[3]  Jifa Zhang,et al.  Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy. , 2022, Journal of medicinal chemistry.

[4]  L. Ouyang,et al.  Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential. , 2022, Journal of medicinal chemistry.

[5]  T. Willson,et al.  Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β-Coronaviruses , 2022, ACS chemical biology.

[6]  Hao Wang,et al.  Design, synthesis and biological evaluation of chromone derivatives as novel protein kinase CK2 inhibitors. , 2022, Bioorganic & medicinal chemistry letters.

[7]  C. Chiang,et al.  Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. , 2021, Journal of medicinal chemistry.

[8]  Jifa Zhang,et al.  DYRK1A inhibitors for disease therapy: Current status and perspectives. , 2021, European journal of medicinal chemistry.

[9]  M. Bellon,et al.  Feedback Loop Regulation between Pim Kinases and Tax Keeps Human T-Cell Leukemia Virus Type 1 Viral Replication in Check , 2021, Journal of virology.

[10]  L. Pinna,et al.  Targeting CK2 in cancer: a valuable strategy or a waste of time? , 2021, Cell death discovery.

[11]  D. Litchfield,et al.  CK2 Regulation: Perspectives in 2021 , 2021, Biomedicines.

[12]  C. Götz,et al.  Molecular Plasticity of Crystalline CK2α' Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity. , 2021, Journal of medicinal chemistry.

[13]  J. Jose,et al.  Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor , 2021, Pharmaceuticals.

[14]  M. Salvi,et al.  Protein kinase CK2: a potential therapeutic target for diverse human diseases , 2021, Signal Transduction and Targeted Therapy.

[15]  B. Kren,et al.  CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines , 2021, Biomedicines.

[16]  S. Gou,et al.  Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition. , 2021, Journal of medicinal chemistry.

[17]  S. Gou,et al.  Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments. , 2021, Journal of medicinal chemistry.

[18]  P. Workman,et al.  A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2. , 2021, Trends in pharmacological sciences.

[19]  T. Hirota,et al.  Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach. , 2021, European journal of medicinal chemistry.

[20]  S. Knapp,et al.  Development of a potent and selective chemical probe for the pleiotropic kinase CK2. , 2020, Cell chemical biology.

[21]  E. Port,et al.  Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease , 2020, Nature Communications.

[22]  L. Ouyang,et al.  PROTACs in breast cancer therapy. , 2020, Future medicinal chemistry.

[23]  M. Salvi,et al.  Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance , 2020, Cellular Oncology.

[24]  Y. Perera,et al.  Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial , 2020, medRxiv.

[25]  K. Stott,et al.  Proposed allosteric inhibitors bind to the ATP site of CK2α , 2020, bioRxiv.

[26]  J. Jose,et al.  Structural and mechanistic basis of the inhibitory potency of selected 2-aminothiazole compounds on protein kinase CK2. , 2020, Journal of medicinal chemistry.

[27]  Andrew R. Leach,et al.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.

[28]  Feng Yue,et al.  IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia. , 2020, Blood.

[29]  G. Del Favero,et al.  Alternaria toxins as casein kinase 2 inhibitors and possible consequences for estrogenicity: a hybrid in silico/in vitro study , 2020, Archives of Toxicology.

[30]  A. Dalle Vedove,et al.  A novel class of selective CK2 inhibitors targeting its open hinge conformation. , 2020, European journal of medicinal chemistry.

[31]  Nanxin Li,et al.  Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma. , 2020, ACS medicinal chemistry letters.

[32]  N. Zhang,et al.  Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design , 2020, Molecules.

[33]  J. Jose,et al.  Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2. , 2020, Bioorganic chemistry.

[34]  L. Ouyang,et al.  Targeting autophagy-related protein kinases for potential therapeutic purpose , 2019, Acta pharmaceutica Sinica. B.

[35]  A. Dalle Vedove,et al.  Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin , 2020, The FEBS journal.

[36]  S. Haidar,et al.  Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors. , 2019, Bioorganic chemistry.

[37]  R. Abagyan,et al.  Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors , 2019, Scientific Reports.

[38]  Q. Guo,et al.  Small molecule modulators targeting protein kinase CK1 and CK2. , 2019, European journal of medicinal chemistry.

[39]  Sun-Mi Park,et al.  Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer , 2019, Gastric Cancer.

[40]  M. Salvi,et al.  The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells , 2019, Oncogenesis.

[41]  M. Ruzzene,et al.  Role of protein kinase CK2 in antitumor drug resistance , 2019, Journal of experimental & clinical cancer research : CR.

[42]  Yoon-Jae Cho,et al.  Casein Kinase 2 inhibition sensitizes medulloblastoma to temozolomide , 2019, Oncogene.

[43]  C. Götz,et al.  Design of CK2β‐Mimicking Peptides as Tools To Study the CK2α/CK2β Interaction in Cancer Cells , 2019, ChemMedChem.

[44]  J. Jose,et al.  Diacritic Binding of an Indenoindole Inhibitor by CK2α Paralogs Explored by a Reliable Path to Atomic Resolution CK2α′ Structures , 2019, ACS omega.

[45]  R. Battistutta,et al.  Inhibitory Properties of ATP-Competitive Coumestrol and Boldine Are Correlated to Different Modulations of CK2 Flexibility. , 2019, Journal of natural products.

[46]  R. Abagyan,et al.  2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site. , 2019, Journal of medicinal chemistry.

[47]  R. Abagyan,et al.  2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. , 2019, Journal of medicinal chemistry.

[48]  M. Scheepstra,et al.  Bivalent Ligands for Protein Degradation in Drug Discovery , 2019, Computational and structural biotechnology journal.

[49]  T. Hirota,et al.  Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth , 2019, Science Advances.

[50]  M. Borad,et al.  Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma123 , 2018, Translational oncology.

[51]  S. Barta,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib , 2019, Clinical Pharmacokinetics.

[52]  S. Gou,et al.  Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway. , 2018, Bioorganic chemistry.

[53]  A. Ciarrocchi,et al.  BRD4 and Cancer: going beyond transcriptional regulation , 2018, Molecular Cancer.

[54]  K. Niefind,et al.  Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases. , 2018, Bioorganic chemistry.

[55]  D. Spring,et al.  Novel non-ATP competitive small molecules targeting the CK2 α/β interface , 2018, Bioorganic & medicinal chemistry.

[56]  S. Fisher,et al.  Targeted protein degradation and the enzymology of degraders. , 2018, Current opinion in chemical biology.

[57]  K. Ye,et al.  CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment , 2018, Frontiers in Molecular Neuroscience.

[58]  J. Jose,et al.  A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors. , 2018, European journal of medicinal chemistry.

[59]  J. Jose,et al.  Unexpected Binding Mode of a Potent Indeno[1,2-b]indole-Type Inhibitor of Protein Kinase CK2 Revealed by Complex Structures with the Catalytic Subunit CK2α and Its Paralog CK2α′ , 2017, Pharmaceuticals.

[60]  S. Zhang,et al.  Association of protein kinase CK2 inhibition with cellular radiosensitivity of non-small cell lung cancer , 2017, Scientific Reports.

[61]  P. Billuart,et al.  CSNK2B splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy , 2017, Human mutation.

[62]  Bai Li,et al.  Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML , 2017, Molecular and Cellular Biochemistry.

[63]  A. Toker,et al.  Cross-talk between the CK2 and AKT signaling pathways in cancer. , 2017, Advances in biological regulation.

[64]  S. Smerdon,et al.  MRE11 stability is regulated by CK2-dependent interaction with R2TP complex , 2017, Oncogene.

[65]  G. Cozza.  The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design , 2017, Pharmaceuticals.

[66]  C. Arús,et al.  Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice , 2017, Pharmaceuticals.

[67]  A. Hjelmeland,et al.  Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells , 2017, Journal of Neuro-Oncology.

[68]  O. Filhol,et al.  In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface , 2017, Pharmaceuticals.

[69]  S. Oltean,et al.  The many faces of SRPK1† , 2017, The Journal of pathology.

[70]  I. Dominguez,et al.  CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target , 2017, Pharmaceuticals.

[71]  A. Poso,et al.  Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining , 2017, Pharmaceuticals.

[72]  Guanglan Zhang,et al.  CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells , 2017, Haematologica.

[73]  Bi-hua Tan,et al.  Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies. , 2016, Current pharmaceutical design.

[74]  K. Jang,et al.  CK2α/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients. , 2016, The American journal of pathology.

[75]  Koji Okamoto,et al.  TNIK inhibition abrogates colorectal cancer stemness , 2016, Nature Communications.

[76]  C. Crews,et al.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.

[77]  Sharyn A. Lincoln,et al.  De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features , 2016, Human Genetics.

[78]  Alessio Ciulli,et al.  Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein–Protein Interactions , 2015, ChemMedChem.

[79]  A. Venerando,et al.  The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation , 2015, BioMed research international.

[80]  Jin Jiang,et al.  Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis , 2015, International journal of molecular sciences.

[81]  M. Hagiwara,et al.  Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice , 2015, Molecular Pharmacology.

[82]  H. Gohlke,et al.  Synthesis, Biological Evaluation and Molecular Modeling of Substituted Indeno[1,2-b]indoles as Inhibitors of Human Protein Kinase CK2 , 2015, Pharmaceuticals.

[83]  O. Issinger,et al.  A Note of Caution on the Role of Halogen Bonds for Protein Kinase/Inhibitor Recognition Suggested by High- And Low-Salt CK2α Complex Structures. , 2015, ACS chemical biology.

[84]  J. Barata,et al.  Kinases, tails and more: regulation of PTEN function by phosphorylation. , 2015, Methods.

[85]  Mingzhou Chen,et al.  Casein Kinase II Controls TBK1/IRF3 Activation in IFN Response against Viral Infection , 2015, The Journal of Immunology.

[86]  Joachim Jose,et al.  Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2. , 2015, Journal of medicinal chemistry.

[87]  A. Serra-Caetano,et al.  Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels , 2014, Haematologica.

[88]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[89]  S. Chi,et al.  Identification of a Novel Function of CX-4945 as a Splicing Regulator , 2014, PloS one.

[90]  J. Barata,et al.  Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia , 2014, Leukemia.

[91]  C. Girardi,et al.  Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential , 2014, Cellular and Molecular Life Sciences.

[92]  L. Cesaro,et al.  Aberrant signalling by protein kinase CK2 in imatinib‐resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives , 2013, Molecular oncology.

[93]  S. Ryu,et al.  Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. , 2013, European journal of pharmacology.

[94]  R. Bertorelle,et al.  Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity , 2013, Journal of Hematology & Oncology.

[95]  Jia-Ren Lin,et al.  Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. , 2013, Molecular cell.

[96]  L. Trentin,et al.  Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells , 2013, PloS one.

[97]  Shu Liu,et al.  Coumestrol from the national cancer Institute’s natural product library is a novel inhibitor of protein kinase CK2 , 2013, BMC Pharmacology and Toxicology.

[98]  David Hsieh,et al.  Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells , 2013, Journal of cellular and molecular medicine.

[99]  O. Issinger,et al.  First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand. , 2013, ACS chemical biology.

[100]  Shwu‐Yuan Wu,et al.  Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.

[101]  S. Moro,et al.  Kinase CK2 inhibition: an update. , 2013, Current medicinal chemistry.

[102]  M. Mizoguchi,et al.  Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma , 2012, Front. Oncol..

[103]  F. Zhou,et al.  Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells , 2012, The Prostate.

[104]  Adam Siddiqui-Jain,et al.  Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. , 2012, Cancer letters.

[105]  E. Tibaldi,et al.  Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. , 2012, Biochemistry.

[106]  F. Totzke,et al.  Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines. , 2012, Biochemical and biophysical research communications.

[107]  F. Totzke,et al.  Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors. , 2012, Bioorganic & medicinal chemistry.

[108]  Kazuo Kitaura,et al.  Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds. , 2012, Journal of medicinal chemistry.

[109]  L. Pinna,et al.  Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A , 2012, Cellular and Molecular Life Sciences.

[110]  M. Ladomery,et al.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. , 2011, Cancer cell.

[111]  Roberto Battistutta,et al.  Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. , 2011, Biochemistry.

[112]  A. Bayless,et al.  CK2 inhibitors increase the sensitivity of HSV-1 to interferon-β. , 2011, Antiviral research.

[113]  S. Yarmoluk,et al.  Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2 , 2011, Molecular and Cellular Biochemistry.

[114]  A. Tefferi,et al.  A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. , 2011, Blood.

[115]  Q. Zeng,et al.  Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes , 2011, Journal of Translational Medicine.

[116]  J. Bain,et al.  ATP site-directed inhibitors of protein kinase CK2: an update. , 2011, Current topics in medicinal chemistry.

[117]  Adam Siddiqui-Jain,et al.  Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. , 2011, Journal of medicinal chemistry.

[118]  A. Ferguson,et al.  Structural basis of CX‐4945 binding to human protein kinase CK2 , 2011, FEBS letters.

[119]  M. Nawijn,et al.  For better or for worse: the role of Pim oncogenes in tumorigenesis , 2011, Nature Reviews Cancer.

[120]  J. Barata,et al.  Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. , 2010, Blood.

[121]  S. Knapp,et al.  New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[122]  Jianhua Shen,et al.  Emodin, a natural product, selectively inhibits 11β‐hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet‐induced obese mice , 2010, British journal of pharmacology.

[123]  B. Guerra,et al.  Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells , 2010, BMC Cancer.

[124]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[125]  J. Barata,et al.  Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and γ-secretase inhibitors , 2010, Haematologica.

[126]  L. Pinna,et al.  Addiction to protein kinase CK2: a common denominator of diverse cancer cells? , 2010, Biochimica et biophysica acta.

[127]  S. Smerdon,et al.  CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response , 2009, Nucleic acids research.

[128]  S. Wölfl,et al.  Fusion of a Short HA2-Derived Peptide Sequence to Cell-Penetrating Peptides Improves Cytosolic Uptake, but Enhances Cytotoxic Activity , 2009, Pharmaceuticals.

[129]  K. Kitaura,et al.  Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. , 2009, Bioorganic & medicinal chemistry letters.

[130]  D. Seldin,et al.  Protein Kinase CK2 in Health and Disease , 2009, Cellular and Molecular Life Sciences.

[131]  Daniela Hoeller,et al.  Targeting the ubiquitin system in cancer therapy , 2009, Nature.

[132]  O. Issinger,et al.  The interaction of CK2α and CK2β, the subunits of protein kinase CK2, requires CK2β in a preformed conformation and is enthalpically driven , 2008, Protein science : a publication of the Protein Society.

[133]  E. Itarte,et al.  The regulatory beta subunit of protein kinase CK2 contributes to the recognition of the substrate consensus sequence. A study with an eIF2 beta-derived peptide. , 2008, Biochemistry.

[134]  Y. Wong,et al.  Identification of chemical inhibitors of protein-kinase CK2 subunit interaction , 2008, Molecular and Cellular Biochemistry.

[135]  O. Issinger,et al.  The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin. , 2008, Journal of molecular biology.

[136]  O. Issinger,et al.  The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. , 2008, Chemistry & biology.

[137]  E. Uriarte,et al.  Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships. , 2008, Journal of medicinal chemistry.

[138]  G. Unger,et al.  Protein kinase CK2--a key suppressor of apoptosis. , 2008, Advances in enzyme regulation.

[139]  D. Mann,et al.  Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human α‐synuclein: Implication for α‐synucleinopathies , 2007 .

[140]  S. Moro,et al.  Tetrabromocinnamic Acid (TBCA) and Related Compounds Represent a New Class of Specific Protein Kinase CK2 Inhibitors , 2007, Chembiochem : a European journal of chemical biology.

[141]  Volodymyr G Bdzhola,et al.  Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. , 2006, Journal of medicinal chemistry.

[142]  F. Barbon,et al.  Multiple myeloma cell survival relies on high activity of protein kinase CK2. , 2006, Blood.

[143]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[144]  Paolo Bonvini,et al.  Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. , 2006, Journal of medicinal chemistry.

[145]  Y. Qiu,et al.  The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs , 2006, Oncogene.

[146]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[147]  Giuseppe Zanotti,et al.  Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. , 2005, Chemistry & biology.

[148]  L. Pinna,et al.  Protein kinase CK2 phosphorylates and upregulates Akt/PKB , 2005, Cell Death and Differentiation.

[149]  A. Zambon,et al.  Development and exploitation of CK2 inhibitors , 2005, Molecular and Cellular Biochemistry.

[150]  D. Litchfield,et al.  The Multiple Personalities of the Regulatory Subunit of Protein Kinase CK2: CK2 Dependent and CK2 Independent Roles Reveal a Secret Identity for CK2β , 2005, International journal of biological sciences.

[151]  J. Bain,et al.  Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. , 2004, Journal of medicinal chemistry.

[152]  S. Moro,et al.  Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. , 2004, Biochemistry.

[153]  L. Pinna,et al.  2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. , 2004, Biochemical and biophysical research communications.

[154]  Dajun Yang,et al.  Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004, Journal of medicinal chemistry.

[155]  D. Fabbro,et al.  Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). , 2003, The Biochemical journal.

[156]  D. Fabbro,et al.  Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. , 2003, Journal of medicinal chemistry.

[157]  L. Pinna,et al.  One‐thousand‐and‐one substrates of protein kinase CK2? , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[158]  D. Litchfield.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. , 2003, The Biochemical journal.

[159]  E. de Moliner,et al.  Structural features underlying selective inhibition of protein kinase CK2 by ATP site‐directed tetrabromo‐2‐benzotriazole , 2001, Protein science : a publication of the Protein Society.

[160]  O. Issinger,et al.  Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme , 2001, The EMBO journal.

[161]  R. Kraft,et al.  Targeting of the transcription factor Max during apoptosis: phosphorylation-regulated cleavage by caspase-5 at an unusual glutamic acid residue in position P1. , 2001, The Biochemical journal.

[162]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[163]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[164]  E. Chambaz,et al.  Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger‐mediated dimerization , 1999, The EMBO journal.

[165]  S. K. Lee,et al.  Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. , 1999, Planta medica.

[166]  D. Schomburg,et al.  Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 Å resolution , 1998, The EMBO journal.

[167]  E. Krebs,et al.  Isolation and characterization of human cDNA clones encoding the alpha and the alpha' subunits of casein kinase II. , 1990, Biochemistry.

[168]  O. Issinger,et al.  Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. , 1990, European journal of biochemistry.

[169]  L. Pinna,et al.  Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. , 1990, European journal of biochemistry.

[170]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.